Stealing Settlers? How IP factors into Online Games

Can Intellectual Property Protect Board Games?

I love board games and have been playing a lot of Settlers of Catan online during the pandemic. I use a site called colonist.io, which is an offshoot, unaffiliated version of the Settlers of Catan game. During my Intellectual Property (IP) class with Professor Ho earlier this year, I wondered how IP rights extend to board games. When we tend to think of IP, we might think of cool technological inventions for patents or Disney’s Mickey Mouse for copyright. IP generally relates to protecting human created products, names, and expressions, and can give its owner rights to protect these.

Continue reading “Stealing Settlers? How IP factors into Online Games”

In the Market for Affordable Medicines

Patents and pandemics.  At first, these two things might not seem too related.  Beyond patenting useful things for a pandemic – personal protective equipment, medicines, etc. – what do they have to do with one another?  Well, it turns out that the COVID-19 pandemic has put the spotlight on how to make patented medicines affordable.

Continue reading “In the Market for Affordable Medicines”

pancakes

Patents and Pancakes

I had a fairly clear idea when I came to Loyola University Chicago School of Law that I wanted to focus on patent law. Having a science background, it seemed like a natural fit given the intersection between patent law and science. However, my interests weren’t solidified until I read patent cases assessing the validity of a patented pancake recipe. You’ll have to learn a little bit about my childhood to understand why those interests solidified though. 

A consistent motivating force throughout my life has been figuring out how things worked. As a kid, whenever I got bored with a toy, I would sneak tools from my dad’s toolbox and take it apart. I wanted to get a better understanding of how the toy worked. Knowing that I’d get a lecture on why I shouldn’t break my toys, I’d try to put them back together—often unsuccessfully. Nevertheless, the hunt for that forbidden knowledge was worth the lecture and one less toy. I needed to figure out how it worked, no matter the consequences.

Continue reading “Patents and Pancakes”

Incentivizing Innovation in Rare Disease Research

You might know that patents exist to incentivize innovation. In other words, the inventor who meets patent standards is given a period of market exclusivity (permitting the inventor to exclude others from various activities involving the patented invention) in exchange for publicly disclosing his/her invention. While this may be sufficient incentive for many technological areas, rare diseases pose a unique challenge.

Drug companies don’t generally target rare diseases. Why? A small patient population means that even if expensive research efforts are successful, there will not be a large return on investment. In 1983, the Orphan Drug Act (ODA) was passed with the intent to solve this problem. Has it worked? The answer to this question is more complicated than it may seem. Continue reading “Incentivizing Innovation in Rare Disease Research”

HP Inc. v. Berkheimer: Will SCOTUS Finally Clarify Patentable Subject Matter?

It’s a case with a humble beginning, just three Red Line stops south of Loyola’s Corboy Law Center, in the United States District Court for the Northern District of Illinois. But this case also has the potential to effect major and much needed change in the realm of patent law. The Honorable John Z. Lee heard HP Inc. v. Berkheimer in 2016, and subsequently, the case worked its way through the appellate courts. The Supreme Court hasn’t yet decided if it will hear the case because for the last eleven months the Petition for Writ of Certiorari for Berkheimer was pending a submission of an amicus brief from the Solicitor General. The brief—which recommended that the Court deny the Berkheimer petition unless another case, Athena v. Mayo, is granted certiorari—was filed with the Court last week. This case could be one of the first patent subject matter eligibility cases to be heard by the Supreme Court in over five years—despite over 40 rejected petitions on the same issue. Subject matter eligibility matters to inventors, investors, and other patent stakeholders, because it directly impacts what does and does not receive a patent, and thus who does or doesn’t have the right to exclusively market and sell their invention as a reward for their creativity and ingenuity. However, the current test for patent subject matter eligibility, introduced in 2014, has been very difficult for the lower courts to administer. If the Supreme Court decides to grant certiorari for Berkheimer, it will have an opportunity to clarify the test. By more explicitly defining what can and cannot be patented, the Supreme Court, in theory, might better align the expectations of patent examiners, judges, and inventors, allowing the patent system to function more efficiently.

Continue reading “HP Inc. v. Berkheimer: Will SCOTUS Finally Clarify Patentable Subject Matter?”

Tolls on Trolls: Can State Laws Stop Patent Trolls?

Trolls are bad. They are bad characters in folk tales. There are also bad internet and social media trolls. Patent trolls join this club. But, what exactly are patent trolls and why have they attracted the attention of the Electronic Frontier Foundation and NPR shows such as This American Life, as well All Tech Considered? That’s what I’m here to tell you about – as well as how to possibly stop/limit patent trolls.

Continue reading “Tolls on Trolls: Can State Laws Stop Patent Trolls?”

An Evolving View on Access to Affordable Medicine

Rising drug prices have led to major issues with providing broad access to medicine around the world. While these issues receive significant media attention, it is important to understand fully why these problems exist in order to come up with real solutions. My perspective is shaped in large part by my background as a scientist. As a researcher, I viewed the issue purely through a scientific lens. I was focused on how to improve the drug development process through the technologies we were creating. However, I realized that there were also legal issues constraining technology development that spurred my interest in attending law school to pursue a career in patent law. As a first-year law student, my perspective has already broadened. I now know about legal barriers that can inhibit the impact of those technologies on global access to improved and cheaper medicine.

Continue reading “An Evolving View on Access to Affordable Medicine”